
Tenet Healthcare (THC) Stock Forecast & Price Target
Tenet Healthcare (THC) Analyst Ratings
Bulls say
Tenet Healthcare reported a strong performance in the third quarter, achieving consolidated net operating revenue of $5.3 billion and an adjusted EBITDA of $1.1 billion, reflecting a 12% year-over-year growth and a 20.8% margin. The company's hospital segment displayed positive trends with a 1.4% increase in adjusted admissions and a 5.9% rise in revenue per adjusted admission, aided by a favorable payor mix and high-acuity cases, which contributed to an improvement in margins. Management has raised revenue guidance, indicating solid operational performance and signaling potential for long-term revenue growth, bolstered by a successful turnaround strategy and strong demand in both hospital and outpatient service segments.
Bears say
The financial outlook for Tenet Healthcare appears negative due to several fundamental concerns, including a disappointing EBITDA increase that was significantly lower than competitors HCA and UHS. Additionally, the company faces risks associated with high exposure to government-sponsored reimbursement programs, a leveraged balance sheet, and geographic concentration that may lead to increased operational volatility. These challenges, coupled with potential labor shortages and shifts in payer mix, raise substantial concerns regarding Tenet's ability to sustain robust financial performance moving forward.
This aggregate rating is based on analysts' research of Tenet Healthcare and is not a guaranteed prediction by Public.com or investment advice.
Tenet Healthcare (THC) Analyst Forecast & Price Prediction
Start investing in Tenet Healthcare (THC)
Order type
Buy in
Order amount
Est. shares
0 shares